WCLC 2025 - Posters & ePosters-P3.18.65 Trial in Progress - RAsolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) Vs. Docetaxel in in Patients With Previously Treated RAS Mutant NSCLC

P3.18.65 Trial in Progress - RAsolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) Vs. Docetaxel in in Patients With Previously Treated RAS Mutant NSCLC

Back to course

Asset Subtitle

Ferdinandos Skoulidis

Meta Tag

Speaker Ferdinandos Skoulidis

Topic Clinical Trials in Progress